Your email has been successfully added to our mailing list.

×
0.0126315789473685 0.0126315789473685 0.0526315789473684 0.0505052631578948 0.0400000000000001 -0.0252631578947369 -0.0315789473684209 0.065263157894737
Stock impact report

Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Po...

Xeris Pharmaceuticals, Inc (XERS)  More Company Research Source: Business Wire
Last xeris pharmaceuticals, inc earnings: 3/11 06:00 am Check Earnings Report
PDF Rebound hypoglycemia observed in the placebo arm with oral glucose tablet use; No rebound hypoglycemia observed in the RTU glucagon treatment arm CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery.This was a Phase 2 prospective, randomized, placebo-controlled, double-blind proof-of-concept study that included an in-clinic stage followed by a 12-week outpatient stage. Subjects were randomly assigned to receive RTU glucagon or placebo during two separate meal challenges in an in-clinic stage crossover design, and then enter a parallel design outpatient stage where they were [Read more]
Impact snapshot Event time: XERS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
XERS alerts

from News Quantified
Opt-in for
XERS alerts

from News Quantified